As attention shifts to what will replace the 2014 Pharmaceutical Price Regulation Scheme (PPRS), Leela Barham provides the first in a series of five features to look at whether the scheme has m
Leela Barham delves into the Department of Health’s accounts to see how contributions from the updated Pharmaceutical Price Regulation Scheme (PPRS) have affected its budget for the NHS since s
As the pharma industry and the Department of Health prepare to negotiate on a successor to the 2014 Pharmaceutical Price Regulation Scheme (PPRS), Leela Barham considers whether the current PPR
Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho